Results 181 to 190 of about 829,629 (331)

Bleeding and Thrombosis in Patients With Out-of-Hospital Ventricular Tachycardia/Ventricular Fibrillation Arrest Treated With Extracorporeal Cardiopulmonary Resuscitation. [PDF]

J Am Heart Assoc
Gutierrez A, Kalra R, Chang KY, Steiner ME, Marquez AM, Alexy T, Elliott AM, Nowariak M, Yannopoulos D, Bartos JA.   +9 more
europepmc   +1 more source

The Application of Artificial Intelligence and Machine Learning in Left Ventricular Assist Device Implantation: A Systematic Review

Artificial Organs, EarlyView.
This systematic review explores the application of artificial intelligence and machine learning in left ventricular assist device implantation, highlighting their superior accuracy in predicting mortality, adverse events, myocardial recovery, thrombosis risk, and right ventricular failure. Despite promising outcomes, challenges like data heterogeneity,
Usama Hussain, Wing Kiu Chou, Abhinav Balasubramanian, Jamolbi Rahmatova, Lydia Wilkinson, Arian Arjomandi Rad, Ioannis Dimarakis, Antonios Kourliouros   +7 more
wiley   +1 more source

Unlocking complex pathways in ventricular tachycardia: Ventricular abnormal activities detection mapping in a case of scar-related multiple ventricular tachycardias. [PDF]

HeartRhythm Case Rep
Kono H, Hiroshima K, Nagashima M, Fukunaga M, Korai K, Ando K.   +5 more
europepmc   +1 more source

Children and Young Adults Who Used Medication for Attention Deficit Hyperactivity Disorder Faced Increased Cardiac Risks

Acta Paediatrica, EarlyView.
ABSTRACT Aim There have been concerns about links between medication for attention deficit hyperactivity disorder (ADHD) and cardiac events in children and young people. Our aim was to identify any associations. Method This Swedish case–control study used national register data to identify individuals aged 5–30 years who received their first diagnosis ...
Howaida Elmowafi, Jenny M. Kindblom, Linda Halldner, David Gyllenberg, Estelle Naumburg   +4 more
wiley   +1 more source

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies

Alimentary Pharmacology &Therapeutics, EarlyView.
In a pooled analysis, bradycardia was observed in 6% of terlipressin‐treated patients but rarely required a dose interruption or reduction. Arrhythmia serious adverse event incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin ...
Jasmohan S. Bajaj, Paul Kwo, Stephen Chris Pappas, Jacqueline G. O'Leary, Khurram Jamil, Sanaz Cardoza, Florence Wong   +6 more
wiley   +1 more source

2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias [PDF]

, 2019
Cuculich, Phillip, et al,
core   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Dual Chamber Open Window Mapping and High-Density Mapping for Atrioventricular Reentrant Tachycardia Associated With Atrioventricular Mahaim Fiber. [PDF]

J Arrhythm
Taomoto Y, Ono Y, Ishida R, Sakamoto T, Otomo K.   +4 more
europepmc   +1 more source

Retrograde Coronary Venous Ethanol Infusion for Ablation of Refractory Ventricular Tachycardia

Circulation: Arrhythmia and Electrophysiology, 2016
Bahij Kreidieh, M. Rodríguez-Mañero, Paul A. Schurmann, S. Ibarra-Cortez, Amish S. Dave, M. Valderrábano   +5 more
semanticscholar   +1 more source

Assessment of the molecular mechanisms of drug‐induced hidden cardiotoxicity by a multi‐omics approach: The example of rofecoxib

British Journal of Pharmacology, EarlyView.
Background and Purpose Hidden cardiotoxicity is defined as drug‐induced cardiotoxicity that becomes obvious only in the presence of comorbidities. However, the molecular mechanisms of hidden cardiotoxicity are not always known. Therefore, unbiased multi‐omics approaches could assist in revealing regulatory pathways.
Bennet Y. Weber, Gábor B. Brenner, Barnabás Váradi, Bence Ágg, Csenger Kovácsházi, Olivér M. Balogh, Donagh Egan, Kieran Wynne, David Matallanas, Rainer Schulz, Péter Ferdinandy, Zoltán Giricz, Anikó Görbe   +12 more
wiley   +1 more source